Company intelligence / Profile preview

BellaSeno

Ownership: Private
Development stage: Clinical

Overview

Interim clinical data from Australian trials show favorable safety profile of resorbable breast scaffolds with no major complications or removals at one year. One-year follow-up showed high breast volume retention (~87%), low complication rates, natural softness, improved quality of life, and successful vascularization at two years. No typical silicone/fat grafting complications observed. Custom-made bone and pectus excavatum scaffolds have received European market access.

Therapeutic areas: OtherRheumatologyWomen's Health
Modalities: DevicePolymer-based scaffold (Resorbable implant)Additive manufacturing (3D-printing)
Industry: Implantable Medical Devices

Partnerships

Collaborations with surgeons/universities such as Macquarie University via Prof. Anand Deva on clinical research/trials.

Beyond the preview

Go deeper on BellaSeno.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BellaSeno.

Explore the full profile